Literature DB >> 28459619

Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy.

Hanif Esmail1,2, Robert J Wilkinson1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28459619      PMCID： PMC5427745          DOI： 10.1513/AnnalsATS.201701-055ED

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  18 in total

1.  British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.

Authors:  J Ledingham; C Wilkinson; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-10       Impact factor: 7.580

Review 2.  Clinical practice. Latent tuberculosis infection in the United States.

Authors:  C Robert Horsburgh; Eric J Rubin
Journal:  N Engl J Med       Date:  2011-04-14       Impact factor: 91.245

3.  From latent to patent: rethinking prediction of tuberculosis.

Authors:  Frank Cobelens; Sandra Kik; Hanif Esmail; Daniela Maria Cirillo; Christian Lienhardt; Alberto Matteelli
Journal:  Lancet Respir Med       Date:  2016-12-22       Impact factor: 30.700

4.  Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.

Authors:  Yael Abitbol; David Laharie; Jacques Cosnes; Matthieu Allez; Stéphane Nancey; Aurélien Amiot; Alexandre Aubourg; Mathurin Fumery; Romain Altwegg; Pierre Michetti; Elise Chanteloup; Philippe Seksik; Clotilde Baudry; Mathurin Flamant; Guillaume Bouguen; Carmen Stefanescu; Anne Bourrier; Gilles Bommelaer; Nina Dib; Marc André Bigard; Stephanie Viennot; Xavier Hébuterne; Jean-Marc Gornet; Philippe Marteau; Yoram Bouhnik; Vered Abitbol; Stéphane Nahon
Journal:  J Crohns Colitis       Date:  2016-07-11       Impact factor: 9.071

5.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

6.  Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection.

Authors:  Erika Bélard; Synne Semb; Morten Ruhwald; Anne Marie Werlinrud; Bolette Soborg; Frank Krieger Jensen; Henrik Thomsen; Annette Brylov; Merete Lund Hetland; Inge Nordgaard-Lassen; Pernille Ravn
Journal:  Inflamm Bowel Dis       Date:  2011-02-11       Impact factor: 5.325

Review 7.  How tumour necrosis factor blockers interfere with tuberculosis immunity.

Authors:  J Harris; J Keane
Journal:  Clin Exp Immunol       Date:  2010-05-18       Impact factor: 4.330

8.  Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Miguel Angel Descalzo
Journal:  Arthritis Rheum       Date:  2007-06-15

Review 9.  Diagnosis and treatment of latent tuberculosis infection.

Authors:  Seung Heon Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-04-02

Review 10.  The ongoing challenge of latent tuberculosis.

Authors:  H Esmail; C E Barry; D B Young; R J Wilkinson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237
View more
  1 in total

1.  Corticosteroid-induced exacerbation of cryptic miliary tuberculosis to acute respiratory distress syndrome: A case report.

Authors:  Minji Song; Sung Jin Kim; Jin Young Yoo
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.